Plain-English translation of NCT07191483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is an early-stage clinical trial testing whether a new medication called KYN-5356 can help improve thinking, memory, and concentration problems that often come with schizophrenia. About 150 adults will take the medication (or a placebo) for 28 days while staying at a clinic so researchers can carefully track how well it works and check for side effects. Some participants will also have tests that measure how the medication affects brain activity.
Many people with schizophrenia struggle with cognitive problems—like difficulty concentrating, remembering things, or processing information—even when their other symptoms are well-controlled by current medications. This trial exists to see whether this medication could help improve these thinking and memory problems, offering a new treatment option for something that current antipsychotic drugs don't adequately address.
You would check into a clinic on Day −3 and stay there for 32 days. Starting on Day 1, you would take a daily oral tablet (either the new medication or placebo) for 28 days. Throughout your stay, you'll have regular check-ins where researchers test your thinking skills, draw blood, monitor your health, and ask about any side effects. Some participants at certain clinic sites will also have special tests that measure electrical activity in the brain. You'll be discharged on Day 29 and return for one final follow-up visit about 2 weeks later.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States